ClinicalTrials.gg
CompletedNCT00794638Updated Jul 2, 2021

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

A Phase 1 interventional study of SyB L-0501 and Rituximab in Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma, sponsored by SymBio Pharmaceuticals. Completed at 4 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-02.

Sponsored by SymBio Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies testing bendamustine in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. bendamustine · Lymphoma, Non-Hodgkin.

Enrollment
37th of 40
9 · median 38
Started
2008
the only one that year
Phase 1
12 of 40
none open now
Registered
8th of 40
by date
Lead sponsor
4 of 40
SymBio Pharmaceuticals

Among the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin, this one is the 37th largest by enrollment, is the only one that started in 2008, is one of 12 in phase 1, and was the 8th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing bendamustine in Lymphoma, Non-Hodgkin as a file.
02

Study summary

The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma

Keywords

  • Non-Hodgkin's Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Mantle cell Lymphoma
  • Transformed lymphoma, transformed to diffuse large B-cell lymphoma
  • Follicular Lymphoma
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aggressive B-cell non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. No restrictions regarding gender.

  • Patients with the following confirmed CD20(+) B-cell non-Hodgkin's lymphoma:

    1. Diffuse large B-cell lymphoma
    2. Mantle cell lymphoma
    3. Transformed lymphoma
    4. Follicular lymphoma (Grade 3)
  • Fail to CR in prior chemotherapy, or relapse following CR or recurrence following PR.
  • Patients who are judged to carry no effect from the prior therapy (cancer chemotherapy, antibody therapy and radiation/ radiotherapy.
  • Patients aged from 20 to 75 years at the time is obtained
  • Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung, liver, and kidney functions)
  • Patients who can be hospitalized during the first cycle
  • Patients capable of personally giving voluntary informed consent in writing to participate in the study

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded.

  • Patients with serious complications (hepatic or renal failure)
  • Patients with complications or medical history of serious cardiac disease (e.g., myocardial infarction, ischemic heart disease)
  • Patients with serious gastrointestinal symptoms (e.g., severe nausea, vomiting, or diarrhea)
  • Patients positive for HBs antigen, antibody, or antibody
  • Patients who received other drug or unapproved medication within 3 months before registration in this study
  • Patients who had history of hematopoietic stem cell transplantation or radioimmunotherapy
  • Patients who are pregnant, of , or lactating
  • Patients, whether male or female, who do not agree to
  • Patients otherwise judged by investigator or sub investigator to be unsuitable
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Interventions

  • The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).

    Also known as: Bendamustine hydrochloride

  • The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity

    Time frame: Treatment period

Secondary outcomes

  1. CR rate and the overall response rate, determination by Independent Review Committee

    Time frame: Treatment period

07

Study locations

4 sites
  • Nagoya-city, Aichi, Japan
  • Isehara-city, Kanagawa, Japan
  • Kyoto-city, Kyoto, Japan
  • Chuo-ku, Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Mar 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2008
First posted
Nov 20, 2008
Start
Nov 2008
Primary completionActual
Mar 2010
CompletionActual
May 2010
Last update
Jul 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00794638
Responsible party
Sponsor
First posted
Nov 20, 2008
Start date
Nov 2008
Primary completion
Mar 2010
Completion
May 2010
Last update
Jul 2, 2021

Study contacts

Kensei Tobinai, MD, Ph D
study chair · National Cancer Center Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Rituximab

Start the discussion